Research Article

Mesenchymal Stem/Stromal Cells from Discarded Neonatal Sternal Tissue: In Vitro Characterization and Angiogenic Properties

Shuyun Wang, Lakshmi Mundada, Eric Colomb, Richard G. Ohye, and Ming-Sing Si

Section of Pediatric Cardiovascular Surgery, Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA

Correspondence should be addressed to Ming-Sing Si; mingsing@umich.edu

Received 28 February 2015; Accepted 22 July 2015

1. Introduction

Mesenchymal stem/stromal cells (MSCs) are known for their proangiogenic qualities and are currently being developed to treat a wide variety of diseases in adults caused or complicated by inadequate tissue perfusion and vascularization [1–5]. Children with congenital heart disease who undergo heart surgery are also affected by diseases of perfusion and vascularization such as congenital coronary anomalies and capillary rarefaction secondary to hypertrophy seen in a multitude of defects [6, 7] or by severe complications of treatment such as stroke [8, 9]. MSC proangiogenic therapy for these pediatric patients would have potential utility but has not been explored. An important consideration for these patients is the tissue source for MSCs, and MSCs from placenta, Wharton’s jelly, and umbilical cord have been described, although contamination of maternal cells may complicate isolate from some of these tissues [10–13].

According to the Society of Thoracic Surgeons National Database, severe congenital heart disease requiring surgical correction in the neonatal and infant period occurs in over 10,000 patients each year in the United States. These patients require surgical correction via a median sternotomy. After median sternotomy, fragments of trabecular bone tissue and some marrow are often present on the sternotomy saw blade or are scattered about the operative field. Here we evaluated our hypothesis that sbMSCs could be isolated from this discarded sternal tissue obtained from neonatal heart surgery and that sbMSCs possess proangiogenic qualities.

2. Materials and Methods

2.1. Sternal Bone MSC Isolation. This study was approved by the University of Michigan Institutional Review Board. Under informed consent, six patients (aged 2–7 days) with hypoplastic left heart syndrome, D-transposition of the great arteries, and truncus arteriosus were included in this study.

After sternotomy with a pneumatic-driven sternal saw (Stryker Corporation, Kalamazoo, MI), bone tissue was...
rinsed off the blade with saline. Free bony fragments in the operative field were also collected. Sternal tissue was then placed into three 10 cm culture dishes. Approximately 3–5 mL of Dulbecco's Modified Eagle Medium, with high-glucose concentration, GlutaMax I, 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin, and 0.25 μg/mL Fungizone (all from Gibco, Carlsbad, CA) were added to partially cover the tissue without detaching the tissue from the dish and then changed every 5 days. After 14–21 days, tissue was rinsed off and cells were trypsinized and replated. Sternal bone MSCs (sbMSCs) were passaged 1:4 when reaching 70% confluency, and all experiments utilized sbMSCs between passages 3–8.

2.2. Colony Forming Unit Efficiency. For colony forming unit efficiency (CFE) determination, sbMSCs (n = 5 patient) were diluted in MSC medium in single cell suspension and plated at 100 cells per 10 cm tissue culture dishes (Corning Life Sciences, Tewksbury, MA). After 14 days of incubation with medium changes every 2-3 days under standard conditions, sbMSCs were washed with PBS, fixed with methanol, and stained with crystal violet. Colonies with >50 cells were counted and recorded.

2.3. Flow Cytometric Characterization. Surface markers of passage 4 sbMSCs (n = 4 patients) were characterized by flow cytometry using antibodies against CD29, CD44, CD45, CD90, CD105, CD73, CD166, CD49e, CD56, STRO-1, CD271, SSEA-4, HLA-ABC, HLA-DR, and nestin (all from BD Biosciences, San Jose, CA, except Stro which was purchased from BioLegend, San Diego, CA) and a Beckman Coulter MoFlo Astrios flow cytometer using the appropriate isotype-matched and unstained controls.

2.4. Trilineage Differentiation Capacity. The multipotency of sbMSCs (n = 4 patients) was investigated using the Human Mesenchymal Stem Cell Functional Identification Kit (R&D Systems Inc., Minneapolis, MN) according to the manufacturer's directions. After incubation in differentiation media for 14–21 days, cells were stained with an anti-osteocalcin antibody, Oil Red O, and anti-FABP-4 antibody, and anti-aggrecan antibody, and imaged using a confocal microscope (Nikon Instruments Inc., Melville, NY). Efficiency of adipogenic differentiation was estimated by the percent area of Oil Red O staining using ImageJ (http://imagej.nih.gov/ij/) and the plugin Threshold Colour (http://www.mecourse.com/landing/software/software.html). Random 100x images (n = 5/ sbMSC line) were filtered by hue followed by the application of a saturation filter. The fraction of remaining pixels relative to the initial total was calculated to yield the percent coverage of staining. One-way ANOVA with post hoc Tukey test was used to compare the difference between Oil Red O staining of the different sbMSC lines.

2.5. Pluripotency Gene Expression. Expression of the pluripotency genes Sox-2, Oct-4, and Nanog was determined in passage 4 sbMSCs (n = 5 patients) relative to human induced pluripotent stem cells (hiPSCs, generously supplied by Dr. Eric Devaney) using qPCR. Total RNA was extracted using the RNAeasy Mini Kit (Qiagen, Valencia, CA). Reverse transcription was carried out using the High Capacity cDNA Reverse Transcription Kit with random primers (Applied Biosystems, Grand Island, NY). Quantitative real-time polymerase chain reaction was performed in StepOne Plus Real-Time PCR system (Applied Biosystems) with a reaction mixture containing cDNA, forward primer, and reverse primer (Table 1), and 1x i Quant Universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA). Fold change in gene expression was calculated based on the 2−ΔΔCT method. Three independent experiments were performed.

2.6. Angiogenic Gene Expression. We evaluated expression for VEGFA, bFGF, ANGI, HIF-1α, and HGF in neonatal sbMSC (n = 6 patients) relative to that in human umbilical vein endothelial cells (HUVECs, from Lonza, Basel, Switzerland) using qPCR. Primers for qPCR analysis are listed in Table 1. Cell monolayers were washed with PBS and then trypsinized. Cells were centrifuged and washed with PBS. For experimental details of qPCR and data analysis, please see above for pluripotency gene analysis. Three independent experiments were performed.

2.7. Sprouting and Tubule Formation. We also explored the ability of sbMSCs to promote sprouting and tubule formation in coculture with HUVECs in three dimensions. Cell cultures were dissociated using trypsin/EDTA, centrifuged, and resuspended in EGM-2 media (Lonza) containing 0.275% methylcellulose (Sigma-Aldrich, St. Louis, MO). Cells in

| Gene    | Forward primer | Reverse primer |
|---------|----------------|----------------|
| β-actin | TCCCTGGAGAAGAGCTACGA | AGACCTGTGTGGCGGTACAG |
| Sox-2   | GGCAGACTCTCTGATGGCTCT | GGAAGTTGGAGATGGGAAAA |
| Oct-4   | GTGTAAGCTGAGAGAAGAGA | CATCGGCTGTGTTATACCC |
| Nanog   | GTTTTGGGCTGGTAGAGAA | TTGGGATCTGGATGGGAAAGT |
| VEGFA   | GCCCTGTCTGTCTACCTCCA | ATGATCTGCTCGCTTCTTGTT |
| bFGF    | GTGTTGATGGAGGATTGTATTTT | CTGCCGGCTAAGGCAATTT |
| ANGI    | GCTCAACATCATCTCCTTATC | CTCAACAGCTCAATCACCCTTC |
| HIF-1α  | CAGCAACTTGAGGAAG TTC | CAGGATGACCTACTTCG |
| HGF     | CTCACACCGCCTGGAGATAC | TTCTTGACCTTGGATGCATT |
Stem Cells International

2.8. Hypoxic sbMSC Conditioned Media Generation. Hypoxia is a pathophysiologic consequence of vascular and perfusion deficits [14, 15]. Hypoxia has also been shown to enhance the proangiogenic properties of the MSC secretome [16–19]. Thus, we determined whether sbMSCs conditioned media in the setting of hypoxia could also promote human umbilical vein endothelial cell (HUVEC) survival and migration. To generate hypoxic conditioned media, sbMSCs (n = 4 patients) were cultured in T75 flask with 6 mL of basal EGM-2 media at 1% O2 using a hypoxic incubator (Eppendorf Inc., Enfield, CT). Conditioned media was then collected at 48 hours and stored at −80°C until used in downstream experiments.

2.9. Endothelial Cell Migration. Promotion of HUVEC migration by hypoxic sbMSC conditioned media was assessed by a scratch assay. To prevent proliferation, HUVECs were treated with 0.01 mg/mL mitomycin C (Sigma-Aldrich) for 2 hours, washed with PBS, and then plated in a 96-well microplate (Essen Biosciences, Ann Arbor, MI) at a density of $2.5 \times 10^4$ cells per well (8 wells/group). Cells were incubated under standard conditions for 24 hours to allow for attachment. A wound maker pin tool (Essen Biosciences) was used to create a scratch in the HUVEC monolayer in each well. Cells were then washed twice prior to addition of hypoxic sbMSC conditioned media. Basal EGM-2 media or supplemented EGM-2 media were added to control wells. Cell migration was monitored at 2-hour intervals for 24 hours and analyzed with CellPlayer Cell Migration Software (Essen Biosciences). Average wound density, confluence, and width were determined at each time point. Independent experiments were performed in duplicate.

2.10. Endothelial Cell Proliferation. The ability of hypoxic sbMSC secretome to promote HUVEC proliferation was evaluated. HUVECs $5 \times 10^3$ cells were plated in each well in a 96-well microplate (6 wells/group) and allowed to attach for 24 hours under standard conditions followed by 24 hours of serum starvation. After 24-hour incubation hypoxic sbMSC conditioned media, basal EGM-2 media or supplemented EGM-2 media were added. After 48-hour incubation, 20 μL of 5 mg/mL of MTT (dimethylthiazol diphenyltetrazolium bromide) in PBS was added to each well and incubated for 4 h at 37°C and 5% CO2. The supernatant was removed and 200 μL dimethyl sulfoxide (Sigma-Aldrich) was added to each well to dissolve the formazan crystals for 20 minutes. Absorbance at 570 nm was then determined with a plate reader (Promega, Madison, WI). Independent experiments were performed in duplicate.

3. Results

Sternal tissue was able to be harvested during neonatal cardiac surgery (Figure 1(a)). After culturing for 14–21 days, MSCs migrated out of adherent trabecular bone fragments.
Figure 2: Characteristics of human neonatal sbMSCs. (a and b) Neonatal sbMSCs were clonogenic as demonstrated by colony forming efficiency. (b) Colony forming efficiency was significantly different between the sbMSC lines by one-way ANOVA followed by post hoc Tukey test, except for the bracketed combinations. (c) Neonatal sbMSCs surface marker characterization by flow cytometry. Results are representative of 3 other lines.

(Figure 1(b)). Neonatal sbMSCs were able to be cryopreserved, thawed, and expanded (data not shown).

Neonatal sbMSCs demonstrated many of the characteristics of bone marrow MSCs. Neonatal sbMSCs were clonogenic (Figures 2(a) and 2(b)) with CFE ranging between 11 and 47%. The surface phenotype of sbMSCs was further evaluated by flow cytometry. Neonatal sbMSCs demonstrated characteristic surface marker phenotype with positive expression for CD29, CD44, CD90, CD105, CD73, CD166, CD49e, and HLA-ABC. Neonatal sbMSCs demonstrated negative expression for CD45, HLA-DR, CD56, CD271, STRO-1, and nestin (Figure 2(c)). There was also a substantial fraction of sbMSCs that were positive for SSEA-4 (Figure 2(c)).

Neonatal sbMSCs were multipotent (Figures 3(a)–3(d)) and cells from different patients appeared to have similar efficiency in osteogenic and chondrogenic differentiation (data not shown) but noticeable differences in adipogenic differentiation, which was quantified by digital image analysis.
Figure 3: Trilineage differentiation of neonatal sbMSCs. Sternal MSCs ($n = 4$ lines) were incubated with differentiation media for 14–21 days. (a) Osteogenic differentiation was demonstrated by anti-osteocalcin staining. (b) Chondrogenic differentiation by anti-aggrecan staining. (c and d) Adipogenic differentiation was demonstrated by Oil Red O and anti-FABP. (c–h) Neonatal sbMSCs cultured in standard growth media did not demonstrate any spontaneous differentiation. (i) Varying efficiency of adipogenic differentiation of sbMSCs by Oil Red O staining as quantified by image analysis. Data were analyzed by one-way ANOVA with post hoc Tukey test and significant differences ($p < 0.05$) are indicated with brackets.

Neonatal sbMSCs that were cultured in standard growth media did not manifest any spontaneous tri-lineage differentiation (Figures 3(f)–3(h)). Neonatal sbMSCs also demonstrated low levels of Sox-2, Oct-4, and Nanog gene expression as compared to hiPSCs, which is consistent with the expression of pluripotency genes in MSCs isolated from other tissues [20–22]. One of the sbMSC lines (line 2) had significantly greater expression of these pluripotency genes as compared to the other lines (Figure 4).

Neonatal sbMSCs also demonstrated proangiogenic properties in vitro. As compared to HUVECs, neonatal sbMSCs demonstrated an increased expression of several angiogenic growth factor genes (Figure 5). VEGFA and ANGI expressions were significantly increased in all sbMSC lines, whereas bFGF, HIF-1α, and HGF were significantly increased in a subset of the analyzed sbMSC lines. While spheroids containing just HUVECs did not manifest any sprouting at 6 days (Figure 6(a)), those that contained sbMSCs manifested increased sprouting (Figure 6(b)). Spheroids with the combination of HUVECs + sbMSCs yielded the most sprouting (Figure 6(c)), which continued to progress over 6 days (Figures 6(d)–6(f)). A subset of these sprouts appeared tube-like (Figures 6(d) and 6(e)) and sprouts from adjacent spheroids were also able to anastomose to one another (Figure 6(f)).
Figure 4: Neonatal sbMSCs express pluripotency-related genes Oct-4, Nanog, and Sox-2 as determined by quantitative real-time PCR. Neonatal sbMSC line 2 had significantly upregulated expression of all these genes as compared to the other lines. Data were analyzed by two-way ANOVA and post hoc Tukey test and significant differences ($p < 0.05$).

Figure 5: Neonatal sbMSCs express angiogenic genes. All neonatal sbMSC lines expressed VEGFA and ANG1 to a greater degree than HUVECs, whereas half of the sbMSC lines evaluated also had increased bFGF expression. Data were analyzed by two-way ANOVA with post hoc Tukey test ($^*$ designates $p < 0.05$ versus HUVECs).

4. Discussion

Consistent with the accepted notion that MSCs are present in almost every tissue [23–25], our results indicate that MSCs can be isolated from small amounts of free bone tissue that is present during the conduct of neonatal cardiac surgeries. We confirmed that neonatal sbMSCs share many characteristics of the prototypic bone marrow derived MSCs: sbMSCs are clonogenic, have surface markers consistent with bone marrow derived MSCs, and are multipotent. In general, the CFE of these sbMSCs was higher than reported for bone marrow derived MSCs isolated from adult donors (7–15%) [26].

MSCs are usually isolated from bone marrow aspirates from long bones or iliac crest of older individuals. MSCs have also been isolated from trabecular bone fragments (femur and tibia) although this technique utilized enzymatic digestion [27–29]. Sottile et al. described a similar nonenzymatic
isolation method of human femur trabecular bone fragments to obtain MSCs [30]. MSCs have also been isolated from adult human sternal marrow [31]. Unique to our study is that we were able to isolate MSCs from normally discarded and overlooked sternal tissue from neonates undergoing cardiac surgery.

The sbMSCs that we have described here may have enhanced therapeutic potential because they come from a neonatal source. It is known that aging abrogates the proliferative and therapeutic potential of bone marrow derived MSCs [26, 32, 33]. While the use of discarded sternal tissue as described in this study required a relatively small amount of tissue from which MSCs can be isolated, larger samples could be harvested without negative effects on the patient. Although these amounts of bone would not be as large as those able to be harvested from an adult, an enhanced proliferative and therapeutic potential of neonatal MSCs may ultimately compensate for this.

We also demonstrated that neonatal sbMSCs possess proangiogenic characteristics in vitro. The tubule formation that we observed when cocultured with HUVECs indicates that sbMSCs functionally promote angiogenesis which is consistent with the behavior of spheroids containing cord blood MSCs and HUVECs as well as adipose MSCs and endothelial progenitor cells [34, 35]. Like MSCs isolated from other tissues, neonatal sbMSCs expressed angiogenic growth factor genes [36, 37]. In conditions of hypoxia (mimicking the in vivo environment in the setting of vascular disease), sbMSCs secreted factors into the conditioned media that were able to promote HUVEC migration as well as surviving from serum starvation. Taken together, these results indicate that neonatal sbMSCs may have potential in promoting angiogenesis in vivo, although this was not examined here directly.

Neonates undergoing heart surgery for complex congenital heart defects have or are at risk of developing diseases of perfusion and vascularization secondary to congenital coronary anomalies and capillary rarefaction secondary to hypertrophy seen in a multitude of defects [6, 7] or caused by severe complications of treatment such as stroke [8, 9]. While others have proposed the potential use of umbilical cord and cord blood derived MSCs to treat neonatal cardiovascular and hypoxic ischemic encephalopathy [38–40], the results of our in vitro studies here suggest that autologous proangiogenic sbMSCs may also have utility in these clinical situations.

5. Conclusions

In conclusion, neonatal sbMSCs share many characteristics with bone marrow derived MSCs and are also proangiogenic. Therefore, discarded neonatal sternal tissue during neonatal cardiac surgery may be a potential source of MSCs for therapeutic use, especially for those pediatric patients with
complex heart disease who have or are at significant risk of developing diseases of perfusion and vascularization.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**Acknowledgment**

This study was supported by the Department of Cardiac Surgery at the University of Michigan.

**References**

[1] G. P. Lasala, J. A. Silva, and J. J. Minguell, “Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product,” *Journal of Thoracic and Cardiovascular Surgery*, vol. 144, no. 2, pp. 377–382, 2012.

[2] P. K. Gupta, A. Chullikana, R. Parakh et al., “A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia,” *Journal of Translational Medicine*, vol. 11, no. 1, article 143, 2013.

[3] A. K. Das, B. J. B. Abdullah, S. S. Dhillon, A. Vijnari, C. H. Anoop, and P. K. Gupta, “Intra-arterial allogeneic mesenchymal stem cells for critical limb ischemia are safe and efficacious: report of a phase I study,” *World Journal of Surgery*, vol. 37, no. 4, pp. 915–922, 2013.

[4] G. P. Lasala, J. A. Silva, B. A. Kusnick, and J. J. Minguell, “Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study,” *Cardiovascular Revascularization Medicine*, vol. 12, no. 1, pp. 29–34, 2011.

[5] D. Lu, B. Chen, Z. Liang et al., “Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial,” Stem Cells International.
[49x221]
[16] L. Chen, Y. B. Xu, J. L. Zhao et al., "Conditioned medium
[49x534]
[10] M. J. Kim, K. S. Shin, J. H. Jeon et al., "Human chorionic-
[49x70]
[19] J. G. Rasmussen, O. Frøbert, L. Pilgaard et al., "Prolonged
[49x124]
[18] A. Burlacu, G. Grigorescu, A.-M. Rosca, M. B. Preda, and
[49x178]
[17] E. K. Jun, Q. Zhang, B. S. Yoon et al., "Hypoxic conditioned
[49x264]
[15] Z. Lokmic, J. Musyoka, T. D. Hewitson, and I. A. Darby,
[49x372]
[13] C. F. Heazlewood, H. Sherrell, J. Ryan, K. Atkinson, C. A. Wells,
[50x480]
[11] R. Anzalone, M. L. Iacono, S. Corrao et al., "New emerg-
[51x748]StemCellsInternational 9
[52x566]
[9] G. Trittenwein, A. Nardi, H. Pansi et al., "Early postoperative
[51x653]
[7] B. Johansson, S. Mörner, A. Waldenström, and P. Stål, "Myocar-
[50x709]CongenitalHeartDisease,vol.92, no.1,pp. 26–36,2011.
[6] N. Kayalar, H. M. Burkhart, J. A. Dearani, F. Cetta, and
[49x146]Diabetes Research and Clinical Practice, vol. 92, no. 1, pp. 26–36,
[52x170]
[25] S. S. Huang, V. Leung, S. L. Peng et al., "Developmental
[23] F. J. Lv, R. S. Tuan, K. M. C. Cheung, and V. Y. L. Leung,

[49x82]

potential of human adipose tissue-derived stem cells," Cytother-
yapy, vol. 13, no. 3, pp. 318–328, 2011.

[20] S. Carelli, F. Messaggio, A. Canazza et al., "Characteristics and
properties of mesenchymal stem cells derived from microfrag-
mented adipose tissue," Cell Transplantation, vol. 24, no. 7, pp.
1233–1252, 2015.

[21] G. Siegel, T. Kluba, U. Hermanutz-Klein, K. Bieback, H.
Northoff, and R. Schäfer, "Phenotype, donor age and gender
affect function of human bone marrow-derived mesenchymal
stromal cells," BMC Medicine, vol. 11, article 146, 2013.

[22] C. Tantrawaipan, S. Manochantr, P. Kheelamai, Y. U.-pratya, A.
Supokawe, and S. Issaragrisil, "Pluripotent gene expression in
mesenchymal stem cells from human umbilical cord Wharton’s
jelly and their differentiation potential to neural-like cells," Journal
of the Medical Association of Thailand, vol. 96, no. 9, pp.
1208–1217, 2013.

[23] F.-J. Lv, R. S. Tuan, K. M. C. Cheung, and V. Y. L. Leung,
"Concise review: the surface markers and identity of human
mesenchymal stem cells," Stem Cells, vol. 32, no. 6, pp.
1408–1419, 2014.

[24] C. Bluguermann, L. Wu, F. Petrigliano, D. Mcallister, S. Mir-
uika, and D. A. Evseenko, "Novel aspects of parenchymal-
mesenchymal interactions: from cell types to molecules and
beyond," Cell Biochemistry and Function, vol. 31, no. 4, pp.
271–280, 2013.

[25] S. S. Huang, V. Leung, S. L. Peng et al., "Developmental
definition of MSCs: new insights into pending questions," Cellular
Reprogramming, vol. 13, no. 6, pp. 465–472, 2011.

[26] G. Siegel, T. Kluba, U. Hermanutz-Klein, K. Bieback, H.
Northoff, and R. Schäfer, "Phenotype, donor age and gender
affect function of human bone marrow-derived mesenchymal
stromal cells," BMC Medicine, vol. 11, no. 1, article 146, 2013.

[27] Y. Sakaguchi, I. Sekiya, K. Yagishita, S. Ichinose, K. Shinomiya,
and T. Muneta, "Suspended cells from trabecular bone by col-
lagenase digestion become virtually identical to mesenchymal
stem cells obtained from marrow aspirates," Blood, vol. 104, no.
9, pp. 2728–2735, 2004.

[28] R. Tuli, S. Tuli, S. Nandi et al., "Characterization of multi-
potential mesenchymal progenitor cells derived from human
trabecular bone," Stem Cells, vol. 21, no. 6, pp. 681–693, 2003.

[29] R. Tuli, M. R. Seghatoleslami, S. Tuli et al., "A simple, high-yield
method for obtaining multipotent mesenchymal progenitor
cells from trabecular bone," Molecular Biotechnology, vol. 23, no.
1, pp. 37–49, 2003.

[30] V. Sottile, C. Halleux, F. Bassilana, H. Keller, and K. Seuwen,
"Stem cell characteristics of human trabecular bone-derived
cells," Bone, vol. 30, no. 5, pp. 699–704, 2002.

[31] V. Paunescu, E. Deak, D. Herman et al., "In vitro differentiation
of human mesenchymal stem cells to epithelial lineage," Journal
of Cellular and Molecular Medicine, vol. 11, no. 3, pp.
502–508, 2007.

[32] F. Z. Asumda, "Age-associated changes in the ecological niche:
implications for mesenchymal stem cell aging," Stem Cell
Research & Therapy, vol. 4, article 47, 2013.

[33] M. S. Choudhery, M. Khan, R. Mahmood, A. Mehmoood, S. N.
Khan, and S. Riazuddin, "Bone marrow derived mesenchymal
stem cells from aged mice have reduced wound healing,
angiogenesis, proliferation and anti-apoptosis capabilities," Cell
Biology International, vol. 36, no. 8, pp. 747–753, 2012.
vasculogenesis,” *Biomaterials*, vol. 32, no. 33, pp. 8446–8455, 2011.

[35] S.-H. Hsu, T.-T. Ho, N.-C. Huang, C.-L. Yao, L.-H. Peng, and N.-T. Dai, “Substrate-dependent modulation of 3D spheroid morphology self-assembled in mesenchymal stem cell-endothelial progenitor cell coculture,” *Biomaterials*, vol. 35, no. 26, pp. 7295–7307, 2014.

[36] D. G. Phinney, “A Sage view of mesenchymal stem cells,” *International Journal of Stem Cells*, vol. 2, no. 1, pp. 1–10, 2009.

[37] A. Bronckaers, P. Hilkens, W. Martens et al., “Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis,” *Pharmacology & Therapeutics*, vol. 143, no. 2, pp. 181–196, 2014.

[38] C. T. J. van Velthoven, A. Kavelaars, and C. J. Heijnen, “Mesenchymal stem cells as a treatment for neonatal ischemic brain damage,” *Pediatric Research*, vol. 71, no. 4, pp. 474–481, 2012.

[39] J. Carroll, “Human cord blood for the hypoxic-ischemic neonate,” *Pediatric Research*, vol. 71, no. 4, pp. 459–463, 2012.

[40] S. C. Peral, H. M. Burkhart, S. Oommen et al., “Safety and feasibility for pediatric cardiac regeneration using epicardial delivery of autologous umbilical cord blood-derived mononuclear cells established in a porcine model system,” *Stem Cells Translational Medicine*, vol. 4, no. 2, pp. 195–206, 2015.